ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2883

The CD4+CD52low T Cell Contributes to the Development of Systemic Lupus Erythematosus through the CCR8/TARC Pathway

Tomohito Sato1, Masataka Umeda1, Tomohiro Koga2, Takashi Igawa1, Syota Kurushima1, Ayuko Takatani1, Toshimasa Shimizu1, Shoichi Fukui1, Ayako Nishino1, Yoshiro Horai1, Shinya Kawashiri1, Naoki Iwamoto1, Yasuko Hirai1, Mami Tamai1, Hideki Nakamura1, Tomoki Origuchi3 and Atsushi Kawakami4, 1Department of Immunology and Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan, 2Department of Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan, 3Department of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 4Department of Immunology and Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki City, Japan

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: T cells and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: CD52 is a cell-surface glycoprotein that is widely expressed in lymphocytes, monocytes and eosinophils. CD4+CD52high T cells inhibit the activation of CD4+CD52low T cells through the release of cell-surface CD52. Soluble CD52, which is cleaved from CD4+CD52high T cells, works as a ligand of siglec-10 on CD4+CD52low T cells (1). CD4+CD52high T cells were reported as distinct population from conventional regulatory T cells. The role of the immune regulation of these cells in systemic lupus erythematosus (SLE) is unknown. We evaluated the CD4+CD52+ T cells in the human peripheral blood mononuclear cells (PBMCs) of SLE patients and clarified their roles in the pathogenesis of SLE.

Methods: We isolated the PBMCs of 58 SLE patients, 22 non-SLE patients (19 with rheumatoid arthritis, 3 with mixed connective-tissue disease) and 33 healthy controls (HCs). The expressions of CD4+CD52high T cells and CD4+CD52low T cells were analyzed by flow cytometry. We also analyzed the correlations with clinical parameters including SLEDAI, anti-ds-DNA antibodies and complement. We then analyzed circulating follicular helper like T cells (Tfh like cells) identified as CD4+CXCR5highICOShighPD-1high and plasmablast identified as CD3–CD19+CD38+CD27+. To determine the genetic characteristics of CD4+CD52low@and CD4+CD52high T cells from SLE, we performed cDNA microarrays (SurePrint G3 Human GE 8x60K) and examined the function of the genes in in-vitro.

Results: We found that the expression of CD4+CD52low T cells in the SLE was significantly higher than HC and non-SLE. The expression of CD4+CD52low T cells of the SLE were positively correlated with SLEDAI, anti-ds-DNA antibodies and IgG. The population of Tfh like cells were increased in SLE and its expression was positively correlated with CD4+CD52low T cells. The microarray analysis revealed that the expression of chemokine receptor 8 (CCR8) is significantly increased in CD4+CD52low T cells. In addition, in vitro experiments using CD4 T cells from patients with SLE showed that thymus and activation-regulated chemokine (TARC), known as a ligand of CCR8, induced the conversion of CD4+CD52high T cells into CD4+CD52low T cells.

Conclusion: Collectively, our data suggest that increased CD4+CD52low T cells along with increased Tfh like cells are involved in the pathogenic autoantibodies production and that TRAC may contributes to the development of SLE via an aberrant induction of CD4+CD52low cells. References@1DNat Immunol. 2013: 14:741-8.


Disclosure: T. Sato, None; M. Umeda, None; T. Koga, None; T. Igawa, None; S. Kurushima, None; A. Takatani, None; T. Shimizu, None; S. Fukui, None; A. Nishino, None; Y. Horai, None; S. Kawashiri, None; N. Iwamoto, None; Y. Hirai, None; M. Tamai, None; H. Nakamura, None; T. Origuchi, None; A. Kawakami, None.

To cite this abstract in AMA style:

Sato T, Umeda M, Koga T, Igawa T, Kurushima S, Takatani A, Shimizu T, Fukui S, Nishino A, Horai Y, Kawashiri S, Iwamoto N, Hirai Y, Tamai M, Nakamura H, Origuchi T, Kawakami A. The CD4+CD52low T Cell Contributes to the Development of Systemic Lupus Erythematosus through the CCR8/TARC Pathway [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/the-cd4cd52low-t-cell-contributes-to-the-development-of-systemic-lupus-erythematosus-through-the-ccr8tarc-pathway/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-cd4cd52low-t-cell-contributes-to-the-development-of-systemic-lupus-erythematosus-through-the-ccr8tarc-pathway/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology